Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a SAD/MAD study of ABX-002 in healthy adults
NL-OMON50699Phase 1Completed
- Sponsor
- Autobahn Therapeutics
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elunetirom in adrenomyeloneuropathy (AMN) (4 arms), sponsored by Autobahn Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 1 more. Started Oct 2021; status: completed.
02
Drugs
elunetirom
03
Conditions
adrenomyeloneuropathy (AMN)
Beyond the preview
Go deeper on NL-OMON50699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50699.